Stilla Technologies, a France based SJE Group investment, has joined an initiative led by Yuzi Holdings and TusPark Science & Technology Service Group (TusPark) to donate two Naica Systems to City of Zhengzhou and City of Xinyang2, in China, to help them better detect the coronavirus and monitor its mutations.
As part of the initiative, Cycloud/Apexbio, Stilla’s distributors and business partners in China, will offer technical support, reagents and kits. Since the beginning of the outbreak, the Chinese Center for Disease Control and Prevention has been working with the Naica System, both at the national level and in the city of Shiyan, in Hubei Province to help strengthen the fight against the epidemic.
Currently, the main method for diagnosing infections uses quantitative PCR (qPCR), a method for which the sensitivity/detection rate remains to be established. An insufficient sensitivity may hamper ongoing efforts to prevent and contain the epidemic, as researchers strive to track the virus mutation rate and its influence on the disease. Digital PCR is an alternative detection method known for its higher sensitivity, accuracy, resolution and tolerance, compared to standard quantitative PCR. The Naica System, the latest generation of digital PCR platforms developed by Stilla Technologies, combined with Cycloud/ Apexbio’s Covid‐2019 detection kits, can provide fast, accurate and reliable DNA/RNA detection of the virus and its mutations.
The SJE Group commends Rémi Dangla (Cofounder and CEO, Stilla Technologies), Yuzi Holdings and TusPark for their efforts.
About Stilla Technologies
Founded in 2013 at Ecole Polytechnique, Stilla Technologies is a Paris‐based European life sciences company that focuses on accelerating the development of next‐generation genetic tests by providing a ground‐breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting‐edge microfluidic innovations, Stilla aims to make dPCR a lab commodity for all areas of the life sciences. Stilla actively advises and supports its customers worldwide through its dynamic and multidisciplinary R&D team, with expertise spanning from microfluidics to chemistry, including molecular biology and AI.